A detailed history of Knott David M Jr transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Knott David M Jr holds 83,000 shares of PTGX stock, worth $7.02 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares
83,000
Previous 80,000 3.75%
Holding current value
$7.02 Million
Previous $4.42 Million 24.7%
% of portfolio
3.06%
Previous 2.81%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$49.7 - $67.42 $149,100 - $202,260
3,000 Added 3.75%
83,000 $5.51 Million
Q2 2025

Aug 11, 2025

BUY
$40.89 - $56.37 $163,560 - $225,480
4,000 Added 5.26%
80,000 $4.42 Million
Q1 2025

May 12, 2025

BUY
$35.09 - $59.76 $829,246 - $1.41 Million
23,632 Added 45.13%
76,000 $3.68 Million
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $873,498 - $1.24 Million
52,368 New
52,368 $873,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $4.15B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Knott David M Jr Portfolio

Follow Knott David M Jr and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

News

Stay updated on Knott David M Jr with notifications on news.